Cassava Sciences has launched a new website, called Rethink-ALZ.com, to make it easier for anyone interested to access information about two Phase 3 clinical studies of simufilam, the company’s oral investigational therapy for mild-to-moderate Alzheimer’s disease. The trials, dubbed RETHINK-ALZ and REFOCUS-ALZ, are ongoing in the U.S. and Canada, and both are currently recruiting patients with Alzheimer’s. “I think clinical sites around the country are quite excited by the potential of oral simufilam to impact Alzheimer’s…
You must be logged in to read/download the full post.
The post Rethink-ALZ.com, New Website on Simufilam Phase 3 Studies, Is Live appeared first on BioNewsFeeds.